Preconditioning the diabetic human myocardium

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 B, 2010, Pages 1740-1746

  Sivaraman, Vivek ^a   Hausenloy, Derek J ^a   Wynne, Abigail M ^a   Yellon, Derek M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diabetes mellitus; Human; Myocardial infarction; Myocardium; Preconditioning

Indexed keywords

PROTEIN KINASE B;

AGED; ARTICLE; CELL HYPOXIA; DIABETES MELLITUS; ENZYMOLOGY; FEMALE; HEART INFARCTION PREVENTION; HEART MUSCLE; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION;

AGED; CELL HYPOXIA; DIABETES MELLITUS; FEMALE; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MIDDLE AGED; MYOCARDIUM; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 77955157002     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00796.x     Document Type: Article

References (45)

1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979, 59:8-13.
2. Mulnier HE, Seaman HE, Raleigh VS. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia. 2008, 51:1639-45.
3. Herlitz J, Wognsen GB, Emanuelsson H. Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care. 1996, 19:698-703.
4. Thourani VH, Weintraub WS, Stein B. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg. 1999, 67:1045-52.
5. Szabo Z, Hakanson E, Svedjeholm R. Early postoperative outcome and medium-term survival in 540 diabetic and 2239 nondiabetic patients undergoing coronary artery bypass grafting. Ann Thorac Surg. 2002, 74:712-9.
6. Abbott RD, Donahue RP, Kannel WB. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. Jama. 1988, 260:3456-60.
7. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986, 74:1124-36.
8. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007, 59:418-58.
9. Ghosh S, Standen NB, Galinianes M. Failure to precondition pathological human myocardium. J Am Coll Cardiol. 2001, 37:711-8.
10. Ishihara M, Inoue I, Kawagoe T. Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 2001, 38:1007-11.
11. Tsang A, Hausenloy DJ, Mocanu MM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes. 2005, 54:2360-4.
12. Mocanu MM, Bell RM, Yellon DM. PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol. 2002, 34:661-8.
13. Tong H, Chen W, Steenbergen C. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res. 2000, 87:309-15.
14. Huisamen B. Protein kinase B in the diabetic heart. Mol Cell Biochem. 2003, 249:31-8.
15. Jonassen AK, Sack MN, Mjos OD. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res. 2001, 89:1191-8.
16. Tomai F, Crea F, Gaspardone A. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation. 1994, 90:700-5.
17. Walker DM, Walker JM, Pugsley WB. Preconditioning in isolated superfused human muscle. J Mol Cell Cardiol. 1995, 27:1349-57.
18. Sivaraman V, Mudalagiri NR, Di Salvo C. Postconditioning protects human atrial muscle through the activation of the RISK pathway. Basic Res Cardiol. 2007, 102:453-9.
19. Hsueh W, Abel ED, Breslow JL. Recipes for creating animal models of diabetic cardiovascular disease. Circ Res. 2007, 100:1415-27.
20. Kristiansen SB, Lofgren B, Stottrup NB. Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia. 2004, 47:1716-21.
21. Smith JM, Wahler GM. ATP-sensitive potassium channels are altered in ventricular myocytes from diabetic rats. Mol Cell Biochem. 1996, 158:43-51.
22. Kersten JR, Schmeling TJ, Orth KG. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol 1998, 275:H721-5.
23. Desrois M, Sidell RJ, Gauguier D. Initial steps of insulin signaling and glucose transport are defective in the type 2 diabetic rat heart. Cardiovasc Res. 2004, 61:288-96.
24. Jonassen AK, Brar BK, Mjos OD. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol. 2000, 32:757-64.
25. Steiler TL, Galuska D, Leng Y. Effect of hyperglycemia on signal transduction in skeletal muscle from diabetic Goto-Kakizaki rats. Endocrinology. 2003, 144:5259-67.
26. Hassouna A, Loubani M, Matata BM. Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. Cardiovasc Res. 2006, 69:450-8.
27. Shinohara T, Takahashi N, Ooie T. Phosphatidylinositol 3-kinase-dependent activation of akt, an essential signal for hyperthermia-induced heat-shock protein 72, is attenuated in streptozotocin-induced diabetic heart. Diabetes. 2006, 55:1307-15.
28. Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes. 2007, 56:127-36.
29. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998, 352:854-65. UK Prospective Diabetes Study (UKPDS) Group
30. Johnson JA, Majumdar SR, Simpson SH. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002, 25:2244-8.
31. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007, 100:328-41.
32. Calvert JW, Gundewar S, Jha S. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 2008, 57:696-705.
33. O'Rourke B. Myocardial K(ATP) channels in preconditioning. Circ Res. 2000, 87:845-55.
34. Minners J, Lacerda L, Yellon DM. Diazoxide-induced respiratory inhibition - a putative mitochondrial K(ATP) channel independent mechanism of pharmacological preconditioning. Mol Cell Biochem. 2007, 294:11-8.
35. Quast U, Stephan D, Bieger S. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004, 53:S156-64.
36. Mocanu MM, Maddock HL, Baxter GF. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001, 103:3111-6.
37. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther. 2004, 18:113-9.
38. Loubani M, Fowler A, Standen NB. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur J Pharmacol. 2005, 515:142-9.
39. Flynn DM, Smith AH, Treadway JL. The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits. Cardiovasc Drugs Ther. 2005, 19:337-46.
40. Siddall HK, Warrell CE, Yellon DM. Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency. Basic Res Cardiol. 2008, 103:560-8.
41. Efthymiou CA, Mocanu MM, Yellon DM. Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol. 2005, 45:247-52.
42. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten. J Am Coll Cardiol. 2005, 45:1287-91.
43. Stratton IM, Adler AI, Neil HA. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000, 321:405-12.
44. Cubbon RM, Wheatcroft SB, Grant PJ. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J. 2007, 28:540-5.
45. Norhammar A, Lindback J, Ryden L. Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart 2007, 93:1577-83.